Credit Suisse’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-94,108
| Closed | -$11.1M | – | 4774 |
|
|
2021
Q1 | $11.1M | Sell |
94,108
-23,695
| -20% | -$2.8M | 0.01% | 1512 |
|
|
2020
Q4 | $13.9M | Buy |
117,803
+102,777
| +684% | +$11.9M | 0.01% | 1378 |
|
|
2020
Q3 | $1.67M | Buy |
15,026
+11,696
| +351% | +$1.26M | ﹤0.01% | 2558 |
|
|
2020
Q2 | $340K | Sell |
3,330
-13,446
| -80% | -$1.44M | ﹤0.01% | 3515 |
|
|
2020
Q1 | $1.81M | Buy |
16,776
+6,964
| +71% | +$800K | ﹤0.01% | 2203 |
|
|
2019
Q4 | $1.14M | Buy |
9,812
+589
| +6% | +$68.2K | ﹤0.01% | 3027 |
|
|
2019
Q3 | $1.06M | Sell |
9,223
-28,138
| -75% | -$2.8M | ﹤0.01% | 2973 |
|
|
2019
Q2 | $3.56M | Sell |
37,361
-28,612
| -43% | -$2.69M | ﹤0.01% | 2018 |
|
|
2019
Q1 | $6.02M | Buy |
+65,973
| New | +$5.4M | 0.01% | 1578 |
|
|
2018
Q4 | – | Sell |
-96,418
| Closed | -$7.71M | – | 4128 |
|
|
2018
Q3 | $7.71M | Buy |
96,418
+68,491
| +245% | +$6.38M | 0.01% | 1416 |
|
|
2018
Q2 | $2.77M | Sell |
27,927
-606,765
| -96% | -$52.4M | ﹤0.01% | 2182 |
|
|
2018
Q1 | $51.4M | Buy |
634,692
+512,787
| +421% | +$41.4M | 0.05% | 408 |
|
|
2017
Q4 | $9.6M | Buy |
121,905
+117,392
| +2,601% | +$9.76M | 0.01% | 1316 |
|
|
2017
Q3 | $417K | Buy |
4,513
+202
| +5% | +$19.4K | ﹤0.01% | 3588 |
|
|
2017
Q2 | $487K | Sell |
4,311
-6,524
| -60% | -$729K | ﹤0.01% | 3166 |
|
|
2017
Q1 | $1.08M | Sell |
10,835
-52,185
| -83% | -$5.58M | ﹤0.01% | 2805 |
|
|
2016
Q4 | $6.78M | Buy |
63,020
+24,642
| +64% | +$2.88M | 0.01% | 1449 |
|
|
2016
Q3 | $4.78M | Buy |
38,378
+2,757
| +8% | +$325K | ﹤0.01% | 1692 |
|
|
2016
Q2 | $3.79M | Sell |
35,621
-5,852
| -14% | -$680K | ﹤0.01% | 1835 |
|
|
2016
Q1 | $4.75M | Buy |
41,473
+6,951
| +20% | +$815K | 0.01% | 1573 |
|
|
2015
Q4 | $4.92M | Buy |
34,522
+26,647
| +338% | +$3.08M | 0.01% | 1590 |
|
|
2015
Q3 | $707K | Buy |
7,875
+2,101
| +36% | +$222K | ﹤0.01% | 3128 |
|
|
2015
Q2 | $665K | Sell |
5,774
-3,952
| -41% | -$415K | ﹤0.01% | 3511 |
|
|
2015
Q1 | $929K | Buy |
9,726
+2,719
| +39% | +$203K | ﹤0.01% | 3032 |
|
|
2014
Q4 | $471K | Sell |
7,007
-1,440
| -17% | -$89.2K | ﹤0.01% | 3755 |
|
|
2014
Q3 | $456K | Buy |
+8,447
| New | +$416K | ﹤0.01% | 3706 |
|
Credit Suisse's CBPO Position: Q2 2021 in Review
Credit Suisse sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 94,108 shares — an estimated $11.1M sold.
Credit Suisse first reported a position in CBPO in Q3 2014 and held it in 26 quarters. The position peaked at $51.4M in Q1 2018. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Credit Suisse reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Credit Suisse sold 94,108 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $11.1M.
- Credit Suisse first reported a position in China Biologic Products Holdings, Inc. in Q3 2014 and held it in 26 quarters.
- Credit Suisse's China Biologic Products Holdings, Inc. position peaked at $51.4M in Q1 2018.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.